<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608062</url>
  </required_header>
  <id_info>
    <org_study_id>06-0537</org_study_id>
    <secondary_id>R01AG027678</secondary_id>
    <nct_id>NCT00608062</nct_id>
  </id_info>
  <brief_title>Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women</brief_title>
  <acronym>SHAPE</acronym>
  <official_title>Biological Mechanisms of Arterial Stiffening With Age and Estrogen Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out why women's arteries stiffen as they go through
      menopause, and how this is affected by estrogen loss. We believe that arteries stiffen with
      the loss of estrogen because of &quot;oxidative stress,&quot; the production of molecules that can
      damage cells and tissues in the body, and because the arteries lose their ability to expand,
      or dilate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As women get older and go through menopause, estradiol levels decrease. Also with aging, the
      arteries that are located around the heart get stiffer. Over time this increase in arterial
      stiffness can lead to a number of health problems such as high blood pressure and heart
      disease. In this study we want to find out if a short-term drop in estrogen levels in
      premenopausal and perimenopausal women can cause arteries to become stiffer, and why this
      happens. Additionally, in postmenopausal women, we want to find out if a short-term increase
      in estrogen levels causes their arteries to become more flexible (less stiff).

      Arterial health (i.e., stiffness) will be examined in premenopausal, perimenopausal and
      postmenopausal women before and after they are given a drug called Ganirelix™ (for 7 days),
      which will markedly lower their reproductive hormones. After the first 4 days of taking
      Ganirelix™, the women will be randomly placed into 1 of 2 treatment groups to take either
      estrogen (0.075 mg/d skin patch) replacement or placebo for the rest of the Ganirelix
      treatment. This is to increase estrogen levels back to the normal level. After having the
      patch on for 4 days, arterial health will be examined again.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial stiffness (carotid artery compliance) during saline and ascorbic acid</measure>
    <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial function - brachial artery flow-mediated dilation</measure>
    <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell protein expression</measure>
    <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum or plasma blood samples - endothelin-1, catecholamines, angiotensin converting enzyme, oxidative stress markers, Interleukin 6 (IL6), C-Reactive Protein (CRP), sex hormones, ascorbic acid, glucose, insulin</measure>
    <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid and brachial blood pressures</measure>
    <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Arterial Stiffening</condition>
  <condition>Aging</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Pre1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premenopausal - GnRHant plus estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Premenopausal - GnRHant plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perimenopausal (early) - GnRHant plus estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Perimenopausal (early) - GnRHant plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perimenopausal (late) - GnRHant plus estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Perimenopausal (late) - GnRHant plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal - GnRHant plus estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Postmenopausal - GnRHant plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRHant - Ganirelix acetate</intervention_name>
    <description>1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7</description>
    <arm_group_label>Pre1</arm_group_label>
    <arm_group_label>Pre2</arm_group_label>
    <arm_group_label>Peri1</arm_group_label>
    <arm_group_label>Peri2</arm_group_label>
    <arm_group_label>Peri3</arm_group_label>
    <arm_group_label>Peri4</arm_group_label>
    <arm_group_label>Post1</arm_group_label>
    <arm_group_label>Post2</arm_group_label>
    <other_name>Ganirelix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal estradiol patch</intervention_name>
    <description>0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
    <arm_group_label>Pre1</arm_group_label>
    <arm_group_label>Peri1</arm_group_label>
    <arm_group_label>Peri3</arm_group_label>
    <arm_group_label>Post1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal placebo patch</intervention_name>
    <description>Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
    <arm_group_label>Pre2</arm_group_label>
    <arm_group_label>Peri2</arm_group_label>
    <arm_group_label>Peri4</arm_group_label>
    <arm_group_label>Post2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women of all races and ethnic backgrounds in one of the following groups:

               -  Premenopausal: 18-49 years, regular menstrual cycles with no change in observed
                  cycle length (21-35 days)

               -  Perimenopausal: 40-55 years, categorized as either early (at least 2 cycles with
                  cycle length changes of at least 7 days) or late (more than 3 months of
                  amenorrhea) transition

               -  Postmenopausal: 45-70 years, more than 12 months of amenorrhea as defined by the
                  menopausal staging system (STRAW); additionally, postmenopausal women will be
                  categorized into early and late stages as defined by the STRAW definition,
                  specifically, women who are less than 5 years postmenopause will be considered
                  early, and women more than 6 years will be categorized as late

          -  All postmenopausal women will have undergone natural menopause

          -  No oral contraceptive or Hormone Replacement Therapy (HRT) use for at least 6 months

          -  Resting blood pressure less than 140/90 mmHg

          -  Plasma glucose concentrations less than 110 mg/dl under fasting conditions

          -  Sedentary or recreationally active (less than 3 days of vigorous aerobic exercise)

          -  No use of medications that might influence cardiovascular function

          -  Nonsmokers

          -  No use of vitamin supplements or willing to stop use for duration of the study

        Exclusion Criteria:

          -  History of or active estrogen-dependent neoplasms, acute liver or gallbladder disease,
             vaginal bleeding, venous thromboembolism, hypertriglyceridemia, and cardiovascular
             disease

          -  Known allergy to transdermal patch or GnRHant

          -  Other contraindications to HRT and GnRHant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerrie L Moreau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research Laboratory</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moreau KL, Donato AJ, Seals DR, DeSouza CA, Tanaka H. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. Cardiovasc Res. 2003 Mar;57(3):861-8.</citation>
    <PMID>12618248</PMID>
  </reference>
  <reference>
    <citation>Moreau KL, Gavin KM, Plum AE, Seals DR. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women. Hypertension. 2005 Jun;45(6):1107-12. Epub 2005 May 2.</citation>
    <PMID>15867135</PMID>
  </reference>
  <reference>
    <citation>Virdis A, Ghiadoni L, Pinto S, Lombardo M, Petraglia F, Gennazzani A, Buralli S, Taddei S, Salvetti A. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation. 2000 May 16;101(19):2258-63.</citation>
    <PMID>10811592</PMID>
  </reference>
  <reference>
    <citation>Ihionkhan CE, Chambliss KL, Gibson LL, Hahner LD, Mendelsohn ME, Shaul PW. Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ Res. 2002 Nov 1;91(9):814-20.</citation>
    <PMID>12411396</PMID>
  </reference>
  <reference>
    <citation>Eskurza I, Monahan KD, Robinson JA, Seals DR. Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. J Physiol. 2004 Apr 1;556(Pt 1):315-24. Epub 2004 Jan 30. Erratum in: J Physiol. 2004 May 1;556(Pt 3):1014.</citation>
    <PMID>14754992</PMID>
  </reference>
  <reference>
    <citation>Gavin KM, Jankowski C, Kohrt WM, Stauffer BL, Seals DR, Moreau KL. Hysterectomy is associated with large artery stiffening in estrogen-deficient postmenopausal women. Menopause. 2012 Sep;19(9):1000-7. doi: 10.1097/gme.0b013e31825040f9.</citation>
    <PMID>22692329</PMID>
  </reference>
  <reference>
    <citation>Moreau KL, Meditz A, Deane KD, Kohrt WM. Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. Am J Physiol Heart Circ Physiol. 2012 Mar 1;302(5):H1211-8. doi: 10.1152/ajpheart.01065.2011. Epub 2012 Jan 13.</citation>
    <PMID>22245769</PMID>
  </reference>
  <results_reference>
    <citation>Moreau KL, Hildreth KL, Meditz AL, Deane KD, Kohrt WM. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab. 2012 Dec;97(12):4692-700. doi: 10.1210/jc.2012-2244. Epub 2012 Sep 11.</citation>
    <PMID>22969140</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>women</keyword>
  <keyword>female</keyword>
  <keyword>estrogen deficiency</keyword>
  <keyword>sex hormones</keyword>
  <keyword>adiposity</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>antioxidants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
    <mesh_term>LHRH, N-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)-</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

